- Home
- HRMY vs EFSC Comparison
HRMY vs EFSC Comparison
Compare HRMY & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- EFSC
- Stock Information
- Founded
- HRMY 2017
- EFSC 1988
- Country
- HRMY United States
- EFSC United States
- Employees
- HRMY N/A
- EFSC N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- EFSC Major Banks
- Sector
- HRMY Health Care
- EFSC Finance
- Exchange
- HRMY Nasdaq
- EFSC Nasdaq
- Market Cap
- HRMY 1.8B
- EFSC 2.0B
- IPO Year
- HRMY 2020
- EFSC 1999
- Fundamental
- Price
- HRMY $34.00
- EFSC $57.36
- Analyst Decision
- HRMY Strong Buy
- EFSC Strong Buy
- Analyst Count
- HRMY 9
- EFSC 3
- Target Price
- HRMY $54.44
- EFSC $64.33
- AVG Volume (30 Days)
- HRMY 642.5K
- EFSC 207.4K
- Earning Date
- HRMY 08-05-2025
- EFSC 07-28-2025
- Dividend Yield
- HRMY N/A
- EFSC 2.10%
- EPS Growth
- HRMY 13.13
- EFSC 9.23
- EPS
- HRMY 2.62
- EFSC 5.09
- Revenue
- HRMY $744,852,000.00
- EFSC $619,222,000.00
- Revenue This Year
- HRMY $20.10
- EFSC $14.06
- Revenue Next Year
- HRMY $18.01
- EFSC $4.85
- P/E Ratio
- HRMY $13.10
- EFSC $11.25
- Revenue Growth
- HRMY 20.62
- EFSC 6.50
- 52 Week Low
- HRMY $26.47
- EFSC $39.47
- 52 Week High
- HRMY $41.61
- EFSC $63.13
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- EFSC 65.09
- Support Level
- HRMY $31.70
- EFSC $56.49
- Resistance Level
- HRMY $35.08
- EFSC $58.17
- Average True Range (ATR)
- HRMY 0.95
- EFSC 1.14
- MACD
- HRMY 0.27
- EFSC 0.23
- Stochastic Oscillator
- HRMY 71.80
- EFSC 85.38
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About EFSC Enterprise Financial Services Corporation
Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.